Stock Events

Stock Events

Santhera Pharmaceuticals 

$23.25
48
+$0.40+1.75% Tuesday 13:30

Statistics

Day High
22.85
Day Low
22.85
52W High
23.25
52W Low
12.28
Volume
100
Avg. Volume
165
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

21SepExpected
Q2 2023
Q1 2024
Q2 2024
Q1 2025
Q2 2025
Q1 2026
Next
-3.03
-2.02
-1.01
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-107.31%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
86.35MRevenue
-92.66MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SPHDF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap1.62B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases, similar to Santhera's focus on Duchenne muscular dystrophy and other mitochondrial and neuromuscular diseases.
PTC Therapeutics
PTCT
Mkt Cap5.88B
PTC Therapeutics is involved in the development of drugs for the treatment of rare disorders, including Duchenne muscular dystrophy, which is a direct competition to Santhera's product pipeline.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.81B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including rare genetic disorders that overlap with Santhera's target market.
Solid Biosciences
SLDB
Mkt Cap724.59M
Solid Biosciences is focused on developing therapies for Duchenne muscular dystrophy, directly competing with Santhera's efforts in the same area.
Wave Life Sciences
WVE
Mkt Cap1.1B
Wave Life Sciences is working on genetically defined diseases, including Duchenne muscular dystrophy, positioning it as a competitor in the same niche as Santhera.
CRISPR Therapeutics
CRSP
Mkt Cap4.9B
CRISPR Therapeutics is engaged in the development of gene-based therapies for serious diseases, including treatments that could potentially compete with Santhera's pipeline for neuromuscular and mitochondrial diseases.
Editas Medicine
EDIT
Mkt Cap383.65M
Editas Medicine operates in the genome editing field, aiming to develop therapies for a range of serious diseases, including those in Santhera's focus area, making it a competitor.
Novartis
NVS
Mkt Cap292.07B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments for neuromuscular diseases, among others, competing with Santhera on a larger scale.
Pfizer
PFE
Mkt Cap149.38B
Pfizer is a global biopharmaceutical company with a diverse portfolio, including research in rare diseases, which could potentially compete with Santhera's niche market.

About

Santhera Pharmaceuticals Holding AG operates as a specialized drug developer that, along with its affiliated entities, focuses on bringing to market therapeutic solutions for uncommon neuromuscular and lung conditions where current treatment options are insufficient. Its operations span the European Union and other global regions. Its most advanced experimental drug, vamorolone, is currently undergoing development to combat Duchenne muscular dystrophy (DMD). The clinical development portfolio also features lonodelestat (known as POL6014), targeting cystic fibrosis and various neutrophilic lung ailments, alongside omigapil, intended for congenital muscular dystrophies. Furthermore, Santhera has granted licensing rights for its approved medication, Raxone (idebenone), used in treating Leber's hereditary optic neuropathy, to partners in territories excluding North America and France. Established in 2004, this company maintains its principal office in Pratteln, Switzerland.
Show more...
CEO
Dr. Thomas Meier Ph.D.
Employees
78
Country
Switzerland
ISIN
CH1276028821

Listings

OTC Link
US
SPHDF
MU
DE
S3F0.MU
STU
DE
S3F0.STU
F
DE
S3F0.F

0 Comments

Share your thoughts

FAQ

What is Santhera Pharmaceuticals stock price today?▼
The current price of SPHDF is $23.25 USD — it has increased by +1.75% in the past 24 hours. Watch Santhera Pharmaceuticals stock price performance more closely on the chart.
What is Santhera Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Santhera Pharmaceuticals stocks are traded under the ticker SPHDF.
When is the next Santhera Pharmaceuticals earnings date?▼
Santhera Pharmaceuticals is going to release the next earnings report on September 21, 2026.
What were Santhera Pharmaceuticals earnings last quarter?▼
SPHDF earnings for the last quarter are -1 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Santhera Pharmaceuticals revenue for the last year?▼
Santhera Pharmaceuticals revenue for the last year amounts to 86.35M USD.
What is Santhera Pharmaceuticals net income for the last year?▼
SPHDF net income for the last year is -92.66M USD.
How many employees does Santhera Pharmaceuticals have?▼
As of June 16, 2026, the company has 78 employees.
In which sector is Santhera Pharmaceuticals located?▼
Santhera Pharmaceuticals operates in the Health & Wellness sector.
When did Santhera Pharmaceuticals complete a stock split?▼
The last stock split for Santhera Pharmaceuticals was on July 03, 2023 with a ratio of 1:10.
Where is Santhera Pharmaceuticals headquartered?▼
Santhera Pharmaceuticals is headquartered in Pratteln, Switzerland.